High-Dose Treatment With Autologous Stem Cell Transplantation in Multiple Myeloma: Past, Present, and Future

Seminars in Hematology

Volumn 44, Issue 4, 2007, Pages 227-233

  Björkstrand, Bo ^a   Gahrton, Gösta ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; BORTEZOMIB; CORTICOSTEROID; INTERLEUKIN 6 ANTIBODY; LENALIDOMIDE; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; RADIOISOTOPE; THALIDOMIDE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; GENE DELETION; GRAFT REJECTION; HEALTH CARE QUALITY; HUMAN; INTERMETHOD COMPARISON; KARYOTYPE; MAINTENANCE THERAPY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FORECASTING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LIFE TABLES; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 35348991080     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2007.08.010     Document Type: Article

References (64)

1. McElwain T.J., and Powles R.L. High dose intravenous melphalan for plasma cell leukaemia and myeloma. Lancet 2 (1983) 822-824
2. Barlogie B., Hall R., Zander A., Dicke K., and Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67 (1986) 1298-1301
3. Björkstrand B., Hagman A., Ljungman P., Reiffers J., Goldschmidt H., Mandelli F., et al. Autologous stem cell transplantation in multiple myeloma-The 2000 EBMT registry update. Bone Marrow Transplant 27 suppl 1 (2001) S40
4. Desikan R., Barlogie B., Sawyer J., Ayers D., Tricot G., Badros A., et al. Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95 (2000) 4008-4010
5. Attal M., Harousseau J.-L., Facon T., Guilhot F., Doyen C., Fuzibet J.-G., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349 (2003) 2495-2502
6. Facon T., Avet-Loiseau H., Guillerm G., Moreau P., Genevieve F., Zandecki M., et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97 (2001) 1566-1571
7. Fassas A.B., Spencer T., Sawyer J., Zangari M., Lee C.K., Anaissie E., et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 118 (2002) 1041-1047
8. Shaughnessy J., Jacobson J., Sawyer J., McCoy J., Fassas A., Zhan F., et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: Interpretation in the context of global gene expression. Blood 101 (2003) 3849-3856
9. Shaughnessy Jr. J., Tian E., Sawyer J., McCoy J., Tricot G., Jacobson J., et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: Early results of total therapy II. Br J Haematol 120 (2003) 44-52
10. Garban F., Attal M., Michallet M., Hulin C., Bourhis J.H., Yakoub-Agha I., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107 (2006) 3474-3480
11. Cavo M., Terragna C., Renzulli M., Zamagni E., Tosi P., Testoni N., et al. Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: Low complete remission rate and short duration of remission. J Clin Oncol 24 (2006) 4-5
12. Björkstrand B., Goldstone A.H., Ljungman P., Brandt L., Brunet S., Carlson K., et al. Prognostic factors in autologous stem cell transplantation for multiple myeloma: An EBMT registry study. Leuk Lymphoma 15 (1994) 265-272
13. Attal M., Harousseau J.L., Stoppa A.M., Sotto J.J., Fuzibet J.G., Rossi J.F., et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335 (1996) 91-97
14. Lahuerta J.J., Martinez-Lopez J., Serna J.D., Blade J., Grande C., Alegre A., et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 109 (2000) 438-446
15. Alexanian R., Weber D., Giralt S., Dimopoulos M., Delasalle K., Smith T., et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 27 (2001) 1037-1043
16. O'Shea D., Giles C., Terpos E., Perz J., Politou M., Sana V., et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: A single-centre experience in 211 patients. Bone Marrow Transplant 37 (2006) 731-737
17. Barlogie B., Tricot G., Rasmussen E., Anaissie E., van Rhee F., Zangari M., et al. Total therapy 2 without thalidomide in comparison with total therapy 1: Role of intensified induction and posttransplantation consolidation therapies. Blood 107 (2006) 2633-2638
18. Badros A., Barlogie B., Siegel E., Roberts J., Langmaid C., Zangari M., et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 114 (2001) 822-829
19. 2 as a surrogate marker of outcome in patients with myeloma. Br J Cancer 85 (2001) 325-332
20. 2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant 35 (2005) 985-990
21. Bird J.M., Fuge R., Sirohi B., Apperley J.F., Hunter A., Snowden J., et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: A British Society of Blood and Marrow Transplantation study. Br J Haematol 134 (2006) 385-390
22. Harousseau J.L., and Attal M. High-dose therapy in multiple myeloma. Hematol J 4 (2003) 163-170
23. Child J.A., Morgan G.J., Davies F.E., Owen R.G., Bell S.E., Hawkins K., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
24. Palumbo A., Bringhen S., Petrucci M.T., Musto P., Rossini F., Nunzi M., et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: Results of a randomized controlled trial. Blood 104 (2004) 3052-3057
25. Barlogie B., Jagannath S., Vesole D.H., Naucke S., Cheson B., Mattox S., et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89 (1997) 789-793
26. Lenhoff S., Hjorth M., Holmberg E., Turesson I., Westin J., Lanng Nielsen J., et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Blood 95 (2000) 7-11
27. Fermand J.P., Katsahian S., Divine M., Leblond V., Dreyfus F., Macro M., et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23 (2005) 9227-9233
28. Blade J., Rosinol L., Sureda A., Ribera J.M., Diaz-Mediavilla J., Garcia-Larana J., et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106 (2005) 3755-3759
29. Barlogie B., Kyle R.A., Anderson K.C., Greipp P.R., Lazarus H.M., Hurd D.D., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 24 (2006) 929-936
30. Harousseau J.L., Milpied N., Garand R., and Bourhis J.H. High dose melphalan and autologous bone marrow transplantation in high risk myeloma. Br J Haematol 67 (1987) 493
31. Vesole D.H., Barlogie B., Jagannath S., Cheson B., Tricot G., Alexanian R., et al. High-dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. Blood 84 (1994) 950-956
32. Björkstrand B., Ljungman P., Bird J.M., Samson D., and Gahrton G. Double high-dose chemo-radiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplant 15 (1995) 367-371
33. Fermand J.-P., Alberti C., and Marolleau J.-P. Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34-enriched ABSC: Results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM). Hematol J 4 suppl 1 (2003) S59
34. Cavo M., Cellini C., Zamagni E., Cangini D., Tacchetti P., Testoni N., et al. Update on high-dose therapy-Italian studies. Haematologica 90 suppl 1 (2005) 39-40
35. Goldschmidt H. Single vs. double high-dose therapy in multiple myeloma: Second analysis of the GMMG-HD2 trial. Haematologica 90 suppl 1 (2005) 38
36. Sonneveld P., van der Holt B., Segeren C.M., Vellenga E., Croockewit A.J., Verhoef G.E.G., et al. Intensive versus double intensive therapy in untreated multiple myeloma: Update analysis of the randomized phase III HOVON 24 study. Haematologica 90 suppl 1 (2005) 37-38
37. Morris C., Iacobelli S., Brand R., Bjorkstrand B., Drake M., Niederwieser D., et al. Benefit and timing of second transplantations in multiple myeloma: Clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol 22 (2004) 1674-1681
38. Turesson I., Zettervall O., Cuzik J., Waldenström J.G., and Velez R. Comparison of trends in the incidence of multiple myeloma in Malmö, Sweden, and other countries. N Engl J Med 310 (1984) 421-424
39. 2) supported by autologous stem cell transplantation is safe and effective in elderly (> or = 65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 37 (2006) 917-922
40. Lenhoff S., Hjorth M., Westin J., Brinch L., Backstrom B., Carlson K., et al. Impact of age on survival after intensive therapy for multiple myeloma: A population-based study by the Nordic Myeloma Study Group. Br J Haematol 133 (2006) 389-396
41. Badros A., Barlogie B., Siegel E., Morris C., Desikan R., Zangari M., et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 114 (2001) 600-607
42. Alexanian R., Haut A., Khan A., Lane M., McKelvey E.M., Migliore P.J., et al. Treatment for multiple myeloma: Combination chemotherapy with different melphalan dose regimens. JAMA 208 (1969) 1680-1685
43. Facon T., Mary J.Y., Hulin C., Benboubker L., Attal M., Renaud M., et al. Major superiority of melphalan-prednison (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood 106 (2005) 230a (abstr)
44. Bird J.M., Bloxham D., Samson D., Marcus R.E., Russell N.H., Kelsey S.M., et al. Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br J Haematol 88 (1994) 110-116
45. Mariette X., Fermand J.-P., and Brouet J.-C. Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy. Bone Marrow Transplant 14 (1994) 47-45 40
46. Stewart A.K., Vescio R., Schiller G., Ballester O., Noga S., Rugo H., et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial. J Clin Oncol 19 (2001) 3771-3779
47. Bourhis JH, Bouko Y, Koscielny S, Bakkus M, Greinix H, Derigs G, et al: Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: Long term follow-up of an EBMT phase III randomized study. Haematologica (in press)
48. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99 (2002) 731-735
49. Dimopoulos M.A., Alexanian R., Przepiorka D., Hester J., Andersson B., Giralt S., et al. Thiotepa, busulfan, and cyclophosphamide: A new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 82 (1993) 2324-2328
50. Schiller G., Nimer S., Vescio R., Lieb G., Lee M., Gajewski J., et al. Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma. Bone Marrow Transplant 14 (1994) 131-136
51. 2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 23 (1999) 1003-1006
52. Giralt S., Bensinger W., Goodman M., Podoloff D., Eary J., Wendt R., et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: Results of two phase 1/2 trials. Blood 102 (2003) 2684-2691
53. Moreau P., Hullin C., Garban F., Yakoub-Agha I., Benboubker L., Attal M., et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: Final results of the prospective and randomized IFM 99-04 protocol. Blood 107 (2006) 397-403
54. Cunningham D., Powles R., Malpas J., Raje N., Milan S., Viner C., et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: Long-term follow-up results. Br J Haematol 102 (1998) 495-502
55. Björkstrand B., Svensson H., Goldschmidt H., Ljungman P., Apperley J., Mandelli F., et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: A retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 27 (2001) 511-515
56. Gojo I., Meisenberg B., Guo C., Fassas A., Murthy A., Fenton R., et al. Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. Bone Marrow Transplant 37 (2006) 65-72
57. Chen C.I., Nanji S., Prabhu A., Beheshti R., Yi Q.L., Sutton D., et al. Sequential, cycling maintenance therapy for post transplant multiple myeloma. Bone Marrow Transplant 37 (2006) 89-94
58. Attal M., Harousseau J.L., Leyvraz S., Doyen C., Hulin C., Benboubker L., et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108 (2006) 3289-3294
59. Björkstrand B., Ljungman P., Svensson H., Hermans J., Alegre A., Apperley J., et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma-A retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 88 (1996) 4711-4718
60. Gahrton G., Svensson H., Cavo M., Apperley J., Bacigalupo A., Björkstrand B., et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-1993 and 1994-1998 at EBMT centers. Br J Haematol 113 (2001) 209-216
61. Bruno B., Rotta M., Patriarca F., Mordini N., Allione B., Carnevale-Schianca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356 (2007) 1110-1120
62. Tricot G., Spencer T., Sawyer J., Spoon D., Desikan R., Fassas A., et al. Predicting long term (>5 yr) event-free survival in multiple myeloma patients following planned tandem autotransplants. Blood 116 (2002) 211-217
63. Oakervee H.E., Popat R., Curry N., Smith P., Morris C., Drake M., et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 129 (2005) 755-762
64. Harousseau J.L., Attal M., Leleu X., Troncy J., Pegourie B., Stoppa A.M., et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study. Haematologica 91 (2006) 1498-1505